文献速递慢性肾脏病

基于综合老年评估的个体化干预逆转老年非透析CKD衰弱:随机对照试验

Randomized Controlled Trial of Individualized Intervention for Frailty Reversal in Older Patients With Nondialysis CKD.
PubMed 文献 · Kidney Int Rep · 2026-05-14

该随机对照试验纳入242例≥65岁、Fried衰弱评分≥3的非透析CKD 3-5期患者,1:1分配至12个月基于综合老年评估的个体化多域干预组或常规照护组。12个月时干预组衰弱逆转率显著高于对照组(30.6% vs 7.4%,P<0.001),年龄校正OR为5.22(95%CI 2.37-11.49);两组非计划住院和全因死亡无显著差异。

要点

  • 基于CGA的个体化干预可安全有效地逆转老年非透析CKD患者衰弱。
  • 12个月衰弱逆转率干预组30.6%,对照组7.4%,差异显著(P<0.001)。
  • 干预未显著改善非计划住院或全因死亡,结论可能不适用于更晚期CKD。

核心结论

  • 基于综合老年评估的个体化干预能有效且安全地逆转老年非透析CKD患者的衰弱。
  • 干预对非计划住院和全因死亡无显著影响,结论可能不适用于更晚期CKD患者。

研究设计与样本

  • 北京朝阳医院开展的随机对照试验,242例年龄≥65岁、Fried评分≥3的3-5期非透析CKD衰弱患者按1:1分组。
  • 干预组接受12个月基于CGA的个体化多域方案(营养、心理、躯体功能),对照组接受常规照护。

主要发现

  • 12个月时干预组衰弱逆转率为30.6%,对照组为7.4%,差异显著(P<0.001)。
  • 年龄校正后,基于CGA的个体化干预与衰弱逆转可能性更高独立相关(OR 5.22,95%CI 2.37-11.49)。
  • 两组非计划住院和全因死亡无显著差异。

关键数值与推荐

  • 衰弱逆转定义:Fried衰弱评分从≥3转为<3。
  • 纳入标准:年龄≥65岁、3-5期非透析CKD、Fried评分≥3;排除预期寿命<1年及沟通困难者。

临床怎么用

  • 对老年非透析CKD衰弱患者,可考虑实施基于CGA的个体化多域干预以促进衰弱逆转。
  • 干预以3期CKD患者为主,对更晚期CKD患者的适用性需谨慎评估。

局限性

  • 研究结论可能不适用于更晚期CKD患者。
  • 未观察到对非计划住院和全因死亡的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Frailty is highly prevalent among older adults with chronic kidney disease (CKD), yet evidence for targeted intervention remains limited. We evaluated whether a comprehensive geriatric assessment (CGA)-based individualized intervention could reverse frailty in this population. METHODS: In this randomized controlled trial conducted at Beijing Chao-yang Hospital, 242 frail patients with CKD (age ≥ 65, stage 3-5 nondialysis CKD, Fried score ≥ 3; excluding life expectancy < 1 year and communication difficulties) were allocated 1:1 to an intervention group receiving a 12-month individualized, CGA-based multidomain program encompassing tailored nutrition, psychological, and physical-function components or to a control group receiving routine care. The primary outcome was frailty reversion at 12 months (transition from Fried frailty score ≥ 3 to < 3), with secondary outcomes of unplanned hospitalization and all-cause mortality. RESULTS: A total of 242 participants were enrolled (mean age 79.98 ± 7.52 years, 55.8% male, 74% had stage 3 CKD). At 12 months, frailty reversion was significantly higher in the intervention group than in the control group (30.6% vs. 7.4%, P < 0.001). Logistic regression confirmed that the CGA-based individualized intervention was independently associated with a higher likelihood of frailty reversion (age-adjusted odds ratio [OR] 5.22, 95% confidence intervals [CI]: 2.37-11.49). No significant differences were observed between groups in unplanned hospitalization or all-cause mortality. CONCLUSION: CGA-based individualized intervention effectively and safely reversed frailty in older nondialysis patients with CKD, predominantly with stage 3 disease. However, no significant impact on unplanned hospitalization or mortality was observed. These findings may not be generalizable to patients with more advanced CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chang J, Liang Y, Jiang Y, et al. Randomized Controlled Trial of Individualized Intervention for Frailty Reversal in Older Patients With Nondialysis CKD. Kidney Int Rep. 2026. PMID: 42305257. doi:10.1016/j.ekir.2026.106595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。